EPC-004

N/A

Report date: 2025/05/14 16:47:18

Base Information

Drug NameEPC-004

Drug Alias NameEPC-004

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionAnti-BCMAAnti-Tumor necrosis factor receptor superfamily member 13B

TargetsB-cell maturation proteinTumor necrosis factor receptor superfamily member 13B

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesElpis BioPharmaceuticals Corp

China Registration ClassN/A

Develop Information

Active CompaniesElpis BioPharmaceuticals Corp

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A